Last reviewed · How we verify
Famotidine (FAM)
Famotidine (FAM) is a H2-receptor antagonist Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved for Duodenal ulcer, Gastric ulcer, Gastroesophageal reflux disease (GERD).
Famotidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells in the stomach.
Famotidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells in the stomach. Used for Duodenal ulcer, Gastric ulcer, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Famotidine (FAM) |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | H2-receptor antagonist |
| Target | Histamine H2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Famotidine competitively inhibits histamine binding to H2 receptors on gastric parietal cells, thereby decreasing both basal and stimulated gastric acid production. This reduction in acid secretion provides symptomatic relief and promotes healing of acid-related gastrointestinal lesions. It is more potent and longer-acting than earlier H2-receptor antagonists like cimetidine.
Approved indications
- Duodenal ulcer
- Gastric ulcer
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Peptic ulcer disease prophylaxis
Common side effects
- Headache
- Dizziness
- Constipation
- Diarrhea
- Fatigue
Key clinical trials
- Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19 (PHASE1)
- Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination (PHASE1)
- Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Famotidine (FAM) CI brief — competitive landscape report
- Famotidine (FAM) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Famotidine (FAM)
What is Famotidine (FAM)?
How does Famotidine (FAM) work?
What is Famotidine (FAM) used for?
Who makes Famotidine (FAM)?
What drug class is Famotidine (FAM) in?
What development phase is Famotidine (FAM) in?
What are the side effects of Famotidine (FAM)?
What does Famotidine (FAM) target?
Related
- Drug class: All H2-receptor antagonist drugs
- Target: All drugs targeting Histamine H2 receptor
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Duodenal ulcer
- Indication: Drugs for Gastric ulcer
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Compare: Famotidine (FAM) vs similar drugs
- Pricing: Famotidine (FAM) cost, discount & access